Showing results (11-20 of 108) with videos related to
Sort By:
Pageof 11
Health Economics|October 3, 2007
Projections of the costs associated with colorectal cancer care in the United States, 2000-2020K Robin Yabroff, Angela B Mariotto, Eric Feuer, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 7, 2024
Assessing 1-Year Comorbidity Prevalence and Its Survival Implications in Medicare Beneficiaries Diagnosed with Cancer: Insights from a New SEER-Medicare ResourceAnne-Michelle Noone, Angela B Mariotto, Yoon Duk Hong, et al.Journal of the National Cancer Institute. Monographs|October 13, 2006
Changing patterns in breast cancer incidence trendsTheodore R Holford, Kathleen A Cronin, Angela B Mariotto, et al.Journal of the National Cancer Institute. Monographs|November 24, 2014
When do changes in cancer survival mean progress? The insight from population incidence and mortalityHyunsoon Cho, Angela B Mariotto, Lisa M Schwartz, et al.Cancer|October 8, 2021
Impact of including second and later cancers in cause-specific survival estimates using population-based registry dataGonçalo Forjaz, Nadia Howlader, Steve Scoppa, et al.Journal of Clinical Epidemiology|October 29, 2011
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesRoman Gulati, Angela B Mariotto, Shu Chen, et al.Journal of the National Cancer Institute. Monographs|October 13, 2006
Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortalityKathleen A Cronin, Angela B Mariotto, Lauren D Clarke, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 12, 2020
Medical Care Costs Associated with Cancer Survivorship in the United StatesAngela B Mariotto, Lindsey Enewold, Jingxuan Zhao, et al.Pharmacoepidemiology and Drug Safety|December 29, 2023
Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indicationYoon Duk Hong, Lindsey Enewold, Michael T Halpern, et al.Medical Care|October 5, 2023
Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the SEER-Medicare DataJoan L Warren, Helen M Parsons, Angela B Mariotto, et al.Pageof 11